We present evidence here that the proinflammatory cytokine, interleukin-1β (IL-1β) stimulates a significant increase in protein kinase C (PKC)-Ε and PKC-δ protein levels and increases PKC-Ε, but not PKC-δ, transcripts in EL4 thymoma cells. Incubation of EL4 cells with IL-1β induced protein synthesis of PKC-Ε (6-fold increase) by 7 h and had a biphasic effect on PKC-δ levels with peaks at 4 h (2-fold increase) and 24 h (4-fold increase). At the level of mRNA, PKC-Ε, but not PKC-δ levels, were induced after incubation of EL4 cells with IL-1β. The signalling mechanisms utilized by IL-1β to induce the synthesis of these PKC isoforms were investigated. Two phosphatidylinositol (PI) 3-kinase-specific inhibitors, wortmannin and LY294002, inhibited IL-1β-induced synthesis of PKC-Ε. However, the PI 3-kinase inhibitors had little effect on the IL-1β-induced synthesis of PKC-δ in these cells. Our results indicate that IL-1β induced both PKC-δ and PKC-Ε expression over different time periods. Furthermore, our evidence suggests that IL-1β induction of PKC-Ε, but not PKC-δ, may occur via the PI 3-kinase pathway.

Keywords:
Interleukin-1, Protein kinase C, Phosphatidylinositol 3-kinase, Wortmannin, LY294002
This content is only available via PDF.
© 2001 S. Karger AG, Basel
2001
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.